TDSPharm Co

TDSPharm Co Equity

The The Equity of TDSPharm Co (464280.KQ) as of Oct 24, 2026 is 42.78 B KRW. In the previous year, The Equity was 38.50 B KRW — a change of 11.12% (higher).

Equity

42.78 BKRW

YoY

11.12%

Last updated:

In 2025, TDSPharm Co's equity was 42.78 B KRW, a 11.12% increase from the 38.50 B KRW equity in the previous year.

The TDSPharm Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2021
16.14 B KRW
Jan 1, 2022
18.31 B KRW
Jan 1, 2023
22.94 B KRW
Jan 1, 2024
38.50 B KRW
Jan 1, 2025
42.78 B KRW
The TDSPharm Co Equity history
YEAREquityYoY
42.78 BKRW+11.12%
38.50 BKRW+67.81%
22.94 BKRW+25.32%
18.31 BKRW+13.42%
16.14 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

TDSPharm Co Stock analysis

What does TDSPharm Co do? TDSPharm Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing TDSPharm Co's Equity

TDSPharm Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding TDSPharm Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating TDSPharm Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

TDSPharm Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in TDSPharm Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about TDSPharm Co stock

The Equity of TDSPharm Co is 42.78 B KRW in 2025.

The Equity of TDSPharm Co changed from 38.50 B KRW to 42.78 B KRW, representing a 11.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity TDSPharm Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's TDSPharm Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — TDSPharm Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — TDSPharm Co